Symbio Signs Five-Year Agreement for OmniComm’s TrialMaster


Applied Clinical Trials

Symbio LLC, a client-focused, full-service clinical research organization, has signed a five-year contract with OmniComm Systems, Inc., a global provider of clinical data management technology. Under the agreement, Symbio will use OmniComm’s TrialMaster version 5 to develop and manage clinical study databases.

Additonally, in 2018, Symbio launched its European operations to support clients with global trials. With the opening of that division, OmniComm’s data center in Europe became a major factor in the selection of TrialMaster. Symbio cited the stability and performance of OmniComm’s EDC technology, TrialMaster’s randomization capability, and the ability to create submission-ready CRFs, ad hoc reports, and customized reports to address sponsors’ needs and requests as contributing factors to its decision.

“We are honored and thrilled that the Symbio management team has selected OmniComm’s TrialMaster platform with its advanced EDC and eSource technology to enhance the services provided to their Sponsor clients,” said Kuno van der Post, PhD, chief commercial officer, OmniComm Systems. “To have another key global CRO choose TrialMaster is very rewarding.”

Related Videos
Related Content
© 2024 MJH Life Sciences

All rights reserved.